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Abstract
Background: Tumour permittivity feedback control is a novel method for microwave ablation (MWA) that
theoretically allows for larger, more predictable ablations. This prospective case series evaluates the
feasibility and efficacy of MWA of liver malignancies using a device with tumour permittivity feedback
control.
Methods: Ten consecutive patients initially determined to be candidates for surgical resection of a liver
malignancy underwent intra-operative MWA with tumour permittivity feedback control followed by a
surgical resection. A 14-gauge Medwaves microwave antenna was used to deliver a single treatment
according to the manufacturer's recommendations. Tumours were assessed grossly as well as by
haematoxylin and eosin (H&E) and tetrazolium chloride staining. The primary end point was per cent
tumour necrosis.
Results: The median maximum ablation diameter measured was 4.1 cm (range 3.0–6.8). The median
ablation volume was 8.7 cm3 (range 4.84–17.55). Six of the 10 tumours demonstrated a pathological
complete response (CR). Six of seven tumours 3 cm demonstrated a pathological CR. Zero of the three
tumours3 cm had a pathological CR, but all had50% tumour necrosis. All patients survived and there
were no ablation-related morbidities.
Discussion: MWA of liver tumours with tumour permittivity feedback control is feasible and appears
effective for the treatment of small (<3 cm) liver tumours.
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Introduction
Thermal ablation by either microwave (MW) or radiofrequency
(RF) has proven efficacy in the treatment of primary and meta-
static liver cancer and has become a standard of care treatment for
selected, small liver tumours not amenable to surgical resection.1
Microwave ablation (MWA) offers several advantages over radi-
ofrequency ablation (RFA), including faster heating over a larger
volume, simultaneous multiple applicator use and no require-
ment for ground pads.2
Recent advances in engineering have allowed for the develop-
ment of an advanced MW device that may allow more uniform
ablations to be created in a shorter period of time compared with
currently available RF and MW systems. The newly designed
Medwaves (San Diego, CA, USA) MWA system has tumour per-
mittivity feedback control which allows real-time monitoring of
ablation conditions and modulation of the power and frequency
of delivered MW energy.3 As biologically active tissues are heated,
properties of permittivity change. Thus, energy deposition can be
maximized and reverse power, a measure of reflectivity, is mini-
mized. By maximizing the amount of delivered forward power,
active heating increases and may induce cellular death more uni-
formly in the target area.3
Because it uses heat, this new device should have complication
rates similar to currently available RF and MW energy devices,
and lower than cryoablation.1 In a recent study in pulmonary
tumours, Wolf et al. 3 demonstrated that MWA with tumour
Previous communication: Brief Oral Presentation at the New England Sur-
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permittivity feedback control results in cytotoxicity and extension
of the ablation zone into aerated peri-tumoral pulmonary paren-
chyma. The purpose of this ablate and resect study is to determine
the feasibility and efficacy of MWA with tumour permittivity
feedback for the treatment of liver tumours.
Materials and methods
Patient population
This ablate and resect prospective study was Institutional Review
Board approved and HIPAA compliant. Between June 2010 and
October 2011, a tumour permittivity feedback control MWA
system was used on 10 patients (5 men, 5 female) that were sched-
uled to undergo curative resection of a liver malignancy by a single
surgeon with 10 years experience in liver tumour ablation.
Informed consent was obtained.
Microwave ablation system
A Medwaves tumour permittivity feedback control MWA system
was used in the ‘temperature control’mode. This generator adapts
to the changing conditions within the ablation zone by continu-
ously and automatically adjusting the power (10–32 Watts) and
frequency (902–928 MHz) of delivered MW energy to maintain a
temperature of 110–120 °C at the microwave antenna active-tip. A
single 14-guage, 2-cm active tip, 15-cm straight antenna was used
in each session to deliver a single 10-min application at the target
temperature. Multiple, overlapping ablations were not permitted
in this study to allow adequate characterization of the ablation
created by a single antennae with a single treatment.
Microwave ablation protocol: ablation and resection
All operations were performed at a single institution by a single
surgeon, and patients were routinely placed under general anaes-
thesia. Using ultrasound guidance, a single, straight microwave
antenna was placed into the tumour, and the generator was
powered in the temperature control mode in accordance with the
manufacturer’s recommendations for 10 min. Upon completion,
the antenna was removed. The tumour including the zone of
ablation and the tract of the antenna was then resected as initially
planned to achieve an R0 resection.
Pathological correlation
The resected liver containing the ablated tumour was transported
en-bloc to the surgical pathology department for analysis. Speci-
mens were grossly inspected by the pathologist. Specimens were
sectioned at 5-mm intervals allowing the ablation zone to be
measured in three dimensions. Scaled digital photos were also
taken. Triphenyl tetrazolium chloride (TTC) staining was per-
formed of representative sections to determine the extent of cel-
lular death. With binary staining characteristics, TTC staining
assays were used to assess viability in regions deemed equivocal on
standard haematoxylin and eosin (H&E) examination. Positive
TTC staining was indicative of tissue viability. A lack of staining
was consistent with cellular death.4 Resection margins were also
analysed in accordance with standard pathological protocol.
Complete necrosis was defined as the absence of neoplastic cells
along with the presence of amorphous material while the diagno-
sis of active neoplasm was based on the demonstration of neo-
plastic cells. Similar to Pompilli et al.,5 the amount of necrosis
within still-viable tumours was estimated on a percentage basis by
a pathologist during microscopic assessment; the nodules were
divided into 4 groups based on the demonstration of complete
necrosis, partial necrosis greater than 50%, partial necrosis less
than 50% and absent necrosis.
Volumetric calculations and data analysis
All tumours were measured in two-dimensions on intra-operative
ultrasound enabling calculation of the median maximum tumor
diameter. Gross measurements in three-dimensions of the abla-
tion zone were made. Approximate ablation zone diameters and
volumes were calculated based upon gross post-resection meas-
urements and the assumption of an ellipsoid geometric shape: V =
1/6•piy•z where V is volume and x, y, and z represent the diameter
along three orthogonal axes.
Results
Between June 2010 and October 2011, a tumour permittivity feed-
back control MWA system was used on 10 patients (5 men and 5
female) that were scheduled to undergo curative resection of a
liver malignancy. Their median age was 55 years (range 42–83).
Three of the tumors were primary hepatocellular carcinomas
(HCCs), two associated with cirrhosis. Seven were metastatic
lesions from colorectal primaries. The median maximal tumour
diameter was 1.9 cm (range 0.7–5.0). On gross inspection, a core
of ablated tan tissue with a surrounding narrow hyperemic rim of
coagulation necrosis was observed (Fig. 1A). The ablated zone was
encompassed by normal parenchyma. With TTC staining, the
non-viable tissue is highlighted (Fig. 1B). The zone of cell death
measured by TTC staining was always greater than the macro-
scopic appearing area by approximately 25%. H&E staining dem-
onstrates findings of coagulation necrosis and ablation-related
architecture alteration (Fig. 2). No large vessels were identified in
or immediately adjacent to any of the ablation zones thereby
prohibiting any comment regarding a heat sink effect in this
series.
Ablation zones weremeasured with amedian ablation long-axis
diameter of 4.1 cm (range 3.0–6.8) and median estimated volume
of 8.7 cm3 (range 4.8–17.6). Six tumours had complete necrosis
and four tumours had partial ablation >50% afterMWA (Table 1).
Six of the seven tumours <3 cm had a complete necrosis response,
and all three of the tumours >3 cm had a partial ablation response
>50% (Table 2).
Discussion
RFA, the most commonly used thermal ablative modality, has an
established role in the treatment of a variety of unresectable
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malignancies owing to its proven efficacy and safety.6,7 RFA as a
complementary or alternative therapy provides a minimally inva-
sive treatment option for selected patients. It is an effective treat-
ment for small (<3 cm) HCCs in cirrhotics awaiting orthotopic
liver transplantation.5,8 RFA provides complete necrosis in
approximately 65% of treated, small hepatomas (<3 cm) in
patients awaiting liver transplant.5,8 Complete response rates fall
to 11–25% when tumour size exceeds 3 cm.5,8
Early data suggest equivalency between RFA and MWA for
ablation of small HCC in terms of both efficacy and morbidity.9–12
MWA has the potential advantage over RFA of being less depend-
ent on tissue properties, as well as, allowing for the generation of
consistently higher intra-tumoural temperatures resulting in
faster ablations, requiring fewer applications per treatment ses-
sion.13 MW energy also minimizes the increase in impedance
caused by RFA. Radiofrequency induced tissue charring results in
increased impedance limiting the spread of energy and therefore,
decreasing ablation size.14
RF electrodes currently available commercially have ablation
algorithms based on temperature or tissue impedance.15 A criti-
cism of the early MWA systems is the lack of feedback from the
tissue level to the antennae as the treatment is being delivered.
MW energy delivered at a frequency of 915 MHz results in
thermal cytotoxic changes at the cellular level that alter the dielec-
tric properties of the tissue. The amount of energy deposited
depends on tissue temperature as well as permittivity. As tissue
temperatures approach 60–70 °C, electrical conductivity increases
by a factor of 1.5–2.0 while permittivity increases only by 5–10%.3
MWAwith tumour permittivity feedback attempts to overcome
this limitation by allowing the generator to adapt to the changing
conditions within the ablation zone by continuously and auto-
matically adjusting the power (10–32Watts) and frequency (902–
928 MHz) of delivered MW energy to maintain a temperature of
110–120 °C at the microwave antenna active-tip and maximize
tissue permittivity. Tumour permittivity feedback offers the theo-
retical advantage of faster, more uniform ablations with less char-
ring and therefore, less impedance compared with conventional
MWA systems that do not provide feedback from the target area
tissue during the ablation. A recent study evaluating MWA with
tumor permittivity feedback in lung tissue, showed ablation
around vessels <4 mm without evidence of heat sink or collateral
damage/thrombosis suggesting the possibility of improved out-
comes compared with conventional forms of thermal ablation.3
The current data shows excellent results with MWA using
tumour permittivity feedback for the treatment of small liver
Figure 1 (A,B) Grossly seen is a post-microwave ablation (MWA) and resection hepatic tumour within the lobectomy specimen. (A) Fresh,
without staining and (B) with triphenyl tetrazolium chloride (TTC) staining highlighting the non-viable area
Figure 2 Haematoxylin and eosin (H&E) (100¥) staining of metastatic
hepatic nodule post-microwave ablation (MWA) and resection.
Ablated metastatic adenocarcinoma (left) with normal liver tissue
(right)
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tumours (<3 cm) using a single antennae, single treatment
approach with complete tumour necrosis in 6/7 treated tumours.
Imaging studies overestimate complete ablation rates.5 Pathologi-
cal evaluation is a more accurate way to determine the effective-
ness of ablation and has been reported after RFA as bridging
therapy in patients undergoing liver transplantation.5,8 Ablate and
resect studies offer another way to more accurately define com-
pleteness of ablation through pathological evaluation. This is the
first ablate and resect study evaluating a MWA system with
tumour permittivity feedback control for the treatment of liver
tumours.
The one tumour <3 cm in the current series that did not have a
complete ablation was the result of a technical failure. After
further evaluation, this may be the result of a satellite tumour
adjacent to the target tumour, although simple misalignment of
the antennae cannot be entirely excluded as a cause.
None of the tumours >3 cm had a complete pathological
response in the current series. This is consistent with previous
reports using other thermal ablation modalities. With a larger
sample size and allowing multiple overlapping ablations these
results would be expected to reach the 10–25% complete response
rate for liver tumours >3 cm previously reported using other
methods of thermal liver tumour ablation.5,8
Furthermore, the current data shows that MWA using a device
with tumour permittivity feedback control is feasible for the treat-
ment of selected liver tumours. In the current series, no immedi-
ate ablation related morbidity was noted. The study design of
resection after ablation has several limitations. The small sample
size and study design does not allow comment on local recurrence
rates, delayed complications and disease-free survival for the
treatment of liver tumours after MWA with tumour permittivity
feedback control.
In conclusion, the current data supports the feasibility of using
MWA with tumour permittivity feedback in the treatment of
selected liver tumours. A larger, prospective, multicentre study
should be performed to better investigate the safety and efficacy in
treating patients who are not candidates for hepatic resection and
to define delayed complications and oncological outcomes after
MWA with tumour permittivity feedback in the treatment of liver
tumours.
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